- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04419298
Cardiac Magnetic Resonance Image (CMR) in Acute Carbon Monoxide (CO) Poisoning
Evaluation for Acute and Chronic Features of Cardiac Injury by CMR in Acute CO Poisoned Patients With Elevated Troponin I (TnI)
Previous report showed that 37% of patients with moderate to severe carbon monoxide (CO) poisoning experienced a myocardial injury, defined as elevated cardiac enzyme [creatine kinase, CK-MB, and cardiac troponin I (TnI)] or ischemic electrocardiogram (ECG) change. In other study, 24% of the patients with the myocardial injury after CO poisoning died during a median follow-up of 7.6 years. The myocardial injury was the major predictor of mortality. In addition, in the Taiwanese nationwide population-based cohort study, CO poisoning itself reported as a higher risk of a major adverse cardiovascular event.
According to the previous study of investigators, among CO poisoned patients with myocardial injury, 74.4% of patients experienced CO-induced cardiomyopathy. All CO-induced cardiomyopathy recovered to normal status. In this situation, there is no definite approved reason why more cardiovascular events are occurred in CO poisoned patients with myocardial injury during long term follow-up period despite normalization of CO-induced elevated TnI and cardiac dysfunction.
Two image cases related to cardiac magnetic resonance imaging (CMR) in acute CO poisoning previously reported. One image case reported that patient had mildly depressed left ventricular (LV) systolic function with hypokinesis of the anterior wall and regional akinesis of the inferior wall on the transthoracic echocardiography performed during hospitalization and late gadolinium-enhancement (LGE) images of CMR demonstrated multiple focal areas of high signal consistent with myocardial necrosis or fibrosis. Another image case reported an image case that in CMR, inferolateral mid-wall myocardial fibrosis, which was defined as LGE, was present despite the setting of a completely normal echocardiogram at 4-month follow-up in CO poisoned patients.
Therefore, the investigators evaluate prevalence (frequency of LGE positive) and patterns (involved LV wall and range of LGE positive) of myocardial fibrosis (LGE positive) in acute CO-poisoned patients during acute (within seven days after CO exposure) and chronic phase (at 4-5 months after CO exposure) and whether LGE positive developed in acute phase have been changed through cardiac MRI performed at chronic phase. The investigators also evaluate LV ejection fraction and global longitudinal strain in transthoracic echocardiography performed at the ED (baseline) and within seven days (follow-up). The investigators also assessed the association between neurocognitive outcomes using the global deterioration scale (at 1, 6, and 12 months after CO exposure) and the presence of LGE positive.
Study Overview
Status
Intervention / Treatment
Detailed Description
In the US, carbon monoxide (CO) poisoning accounts for 1,300 deaths and 50,000 emergency department visits annually. Previous report showed that 37% of patients with moderate to severe CO poisoning experience a myocardial injury defined as elevated cardiac enzyme [creatine kinase, CK-MB, and cardiac troponin I (TnI)] or ischemic electrocardiogram (ECG) change. In other study, there was a mortality of 24% of patients during a median follow-up of 7.6 years. A mortality among the patients who experienced the myocardial injury was higher than patients without the myocardial injury. The death caused by cardiovascular problems occurred more among patients with a history of the myocardial injury (44% vs. 18%). The myocardial injury was the major predictor of mortality. In addition, in the Taiwanese nationwide population-based cohort study, a history of CO poisoning showed a higher risk of a major adverse cardiovascular event.
The investigators reported that myocardial injury (defined as elevated TnI or change of ischemic ECG) developed in 20% of CO poisoned patients and elevated TnI was normalized within 65.0 hours. According to previous study of the investigators, among CO poisoned patients with myocardial injury, 74.4% of patients experienced CO-induced cardiomyopathy. All CO-induced cardiomyopathy recovered to normal status. In this situation, there is no definite approved reason why more cardiovascular events are occurred in CO poisoned patients with myocardial injury during long term follow-up period despite normalization of CO-induced elevated TnI and cardiac dysfunction.
One case reported an image related to a CO poisoned patient with acute myocardial injury found by cardiac magnetic resonance imaging (CMR) with a normal coronary artery confirmed by coronary angiography. In that case, a patient showed that patient had mildly depressed left ventricular (LV) systolic function with hypokinesis of the anterior wall and regional akinesis of the inferior wall on the transthoracic echocardiography performed during hospitalization and late gadolinium-enhancement (LGE) images of CMR demonstrated multiple focal areas of high signal consistent with myocardial necrosis or fibrosis. Through this case, the investigators thought that CO poisoning might result in acute myocardial necrosis, demonstrating another type of myocardial injury that can be detected by CMR. In addition, Other case reported an image case that in cardiac MRI, inferolateral mid-wall myocardial fibrosis, which was defined as LGE, was present despite the setting of a completely normal echocardiogram at 4-month follow-up in a patient who experienced severe CO poisoning.
Mid-wall myocardial fibrosis has been reported in dilated cardiomyopathy (DCMP) of unclear origin. In a follow-up study of 101 consecutive patients with DCMP, mid-wall fibrosis (presented in 35% of patients) predicted a combined endpoint of all-cause mortality, cardiovascular hospitalization, and sudden cardiac death. Myocardial fibrosis has also been demonstrated in hypertrophic cardiomyopathy. The myocardial fibrosis has been linked to known markers for sudden cardiac death, although the independent prognostic value of CMR has yet to be determined.
Through above results, the investigators thought that the normal LV cardiac function may not reflect that there is no problem with the heart, and it could lead to myocardial fibrosis in the chronic phase. Myocardial damage seen through CMR may be related to the patient's prognosis. Therefore, the investigators evaluate prevalence (frequency of LGE positive) and patterns (involved LV wall and range of LGE positive) of myocardial fibrosis (LGE positive) in acute CO-poisoned patients during acute (within 7 days after CO exposure) and chronic phase (at 4-5 months after CO exposure) and whether LGE positive developed in the acute phase has been changed in cardiac MRI performed at chronic phase. The investigators also evaluate LV ejection fraction and global longitudinal strain in transthoracic echocardiography performed at the ED (baseline) and within seven days (follow-up). The investigators also assessed the association between neurocognitive outcomes using the global deterioration scale (at 1, 6, and 12 months after CO exposure) and the presence of LGE positive.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Gangwon
-
Wonju, Gangwon, Korea, Republic of, 26426
- Wonju Severance Christian Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Acute CO poisoning with myocardial injury, which was defined as elevated TnI (reference range < 0.045 ng/mL), within 24 hours after ED arrival.
Exclusion Criteria:
- Age <19 years
- No elevated TnI within 24 hours after ED arrival
- Cardiac arrest upon ED arrival or before taking a CMR
- Co-ingestion of cardiac toxic drugs
- Transferred patients without admission
- Declined to enrollment in the study
- Impossible CMR due to artificial device
- Calculated creatinine clearance (Ccr) < 30 mL/min
- Previous known history of hypersensitivity of gadolinium
- History of acute coronary syndrome, heart failure, or cardiomyopathy
- Patients who refuse CMR or fail to take a CMR although written informed consent was obtained
- Impossible of interpretation of CMR although CMR was taken
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Acute CO poisoning with myocardial injury
A diagnosis of CO poisoning was made according to medical history and carboxyhaemoglobin >5% (>10% in smokers). Myocardial injury was defined as elevated high-sensitivity TnI level above the upper limit (> 0.046 ng/mL) when measured in the emergency department (ED) or repeatedly within 24 hours after ED arrival. |
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Late gadolinium enhancement (LGE) in CMR
Time Frame: Within 7 days after acute CO poisoning
|
Prevalence (percent) of presence of LGE in CMR
|
Within 7 days after acute CO poisoning
|
LGE involved wall in CMR
Time Frame: Within 7 days after acute CO poisoning
|
Injured left ventricular wall according to LGE in CMR
|
Within 7 days after acute CO poisoning
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LGE size in CMR
Time Frame: Within 7 days after acute CO poisoning
|
Injury size according to LGE in CMR
|
Within 7 days after acute CO poisoning
|
Change of LGE between first CMR and follow-up CMR
Time Frame: Within 7 days after CO exposure and at 4-5 months after CO exposure
|
Change of LGE between first CMR (within 7 days after CO exposure) and follow-up CMR (at 4-5 months after CO exposure)
|
Within 7 days after CO exposure and at 4-5 months after CO exposure
|
LV ejection fraction (EF) of TTE performed at the ED
Time Frame: Within 3 hours at the ED
|
Baseline LV EF of TTE performed at the ED
|
Within 3 hours at the ED
|
LV global longitudinal strain (GLS) of TTE performed at the ED
Time Frame: Within 3 hours at the ED
|
Baseline LV GLS of TTE performed at the ED
|
Within 3 hours at the ED
|
LV EF of TTE performed during admission
Time Frame: Within 7 days after CO exposure
|
Follow-up LV EF of TTE performed during admission
|
Within 7 days after CO exposure
|
LV GLS of TTE performed during admission
Time Frame: Within 7 days after CO exposure
|
Follow-up LV GLS of TTE performed during admission
|
Within 7 days after CO exposure
|
Change of LV EF between ED TTE and follow-up TTE
Time Frame: Within 3 hours at the ED and within 7 days after CO exposure
|
Change of LV EF between baseline TTE and follow-up TTE
|
Within 3 hours at the ED and within 7 days after CO exposure
|
Change of LV GLS between ED TTE and follow-up TTE
Time Frame: Within 3 hours at the ED and within 7 days after CO exposure
|
Change of LV GLS between baseline TTE and follow-up TTE
|
Within 3 hours at the ED and within 7 days after CO exposure
|
Correlation between presence of LGE and poor neurocognitive outcome at 1, 6, and 12 months
Time Frame: GDS (minimum 1 - maximum 7) evaluated at 1, 6, and 12 months after CO exposure
|
Correlation between presence of LGE and poor neurocognitive outcome [global deterioration scale (GDS) 4-7] evaluated by GDS at 1, 6, and 12 months after CO exposure
|
GDS (minimum 1 - maximum 7) evaluated at 1, 6, and 12 months after CO exposure
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMR-CO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Injury
-
Damascus UniversityCompletedMyocardial Injury | Cardiac Surgery | Myocardial ProtectionSyrian Arab Republic
-
University Hospital Schleswig-HolsteinAbbott; Department of Anaesthesiology and Intensive Care MedicineCompletedMyocardial InjuryGermany
-
Mahidol UniversityCompletedMyocardial InjuryThailand
-
Rigshospitalet, DenmarkCompletedMyocardial InjuryDenmark
-
Minneapolis Veterans Affairs Medical CenterActive, not recruitingMyocardial InjuryUnited States
-
Zealand University HospitalCompleted
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedMyocardial InjuryNorway
-
Baskent UniversityUnknown
-
Beijing Friendship HospitalUnknownReperfusion Injury, Myocardial | STEMI - ST Elevation Myocardial InfarctionChina
-
Thomas EngstromActive, not recruitingST Elevation Myocardial Infarction | Myocardial Injury | Inflammatory Response | Myocardial Reperfusion InjuryDenmark
Clinical Trials on Cardiac MRI
-
University of FloridaOcala Royal DamesActive, not recruitingBreast CancerUnited States
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI); Nationwide Children's Hospital and other collaboratorsActive, not recruitingPulmonary Hypertension | Congenital Heart Disease | Pediatric Congenital Heart DiseaseUnited States
-
Imperial College LondonNational Institute for Health Research, United Kingdom; Imperial College Healthcare...WithdrawnMyocardial Fibrosis | Heart Failure | End Stage Renal Failure on Dialysis | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe)United Kingdom
-
St. Jude Children's Research HospitalRecruitingSepsis | Acute Respiratory Distress Syndrome | Cardiovascular ShockUnited States
-
University Medical Center GoettingenNot yet recruitingTetralogy of Fallot | Congenital Heart DiseaseGermany
-
Cedars-Sinai Medical CenterRecruitingHealthyUnited States
-
Medical University of GrazEnrolling by invitationPulmonary Hypertension | Elevated Mean Pulmonary Arterial Pressure | Normal Mean Pulmonary Arterial PressureAustria
-
Cedars-Sinai Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); University of Pittsburgh; University...Active, not recruitingCardiovascular DiseaseUnited States
-
University Hospital Birmingham NHS Foundation TrustUnknownTetralogy of FallotUnited Kingdom
-
University Hospital Birmingham NHS Foundation TrustUnknownCardiomyopathiesUnited Kingdom